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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness of non-pharmacological interventions designed to prevent delirium in hospitalised non-intensive care unit
(ICU) patients.
B A C K G R O U N D
Description of the condition
Delirium is a disturbance of consciousness and cognition, which
usually has a rapid onset and a fluctuating course. The core features
of delirium are defined in the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition, and include a “disturbance in at-
tention, awareness and cognition, which develops over a short pe-
riod of time and tends to fluctuate in severity during the course of
a day. It represents an acute change from baseline and is not better
explained by a pre-existing, established or evolving neurocognitive
disorder or a severely reduced level of arousal such as coma. There
should be evidence from history, physical examination or labora-
tory findings that the disturbance is a direct physiological conse-
quence of another medical condition, substance intoxication or
withdrawal, or exposure to a toxin, or is due tomultiple etiologies”
(American Psychiatric Association 2013). The International Statis-
tical Classification of Diseases and Related Health Problems 10th Re-
vision (ICD-10) definition of delirium is similar, but also includes
disturbance of the sleep-wake cycle and does not specify that there
is a definitive underlying aetiology (World Health Organization
2016).
Delirium is highly prevalent across all inpatient hospital settings.
A recent Swiss study evaluated all inpatients and found a period
prevalence of 28% (Schubert 2018). The highest prevalence rates
were found in patients who had experienced cardiac surgery, neu-
rosurgery, trauma, radiotherapy and neurology (36% to 41%).
However, delirium was also common in geriatric medicine, inter-
nal medicine, general surgery, reconstructive plastic surgery and
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cranio-maxillo-facial surgery (22% to 29%) (Schubert 2018). A
point prevalence study conducted in Ireland found that 20% of
adult hospital inpatients had delirium on a single day and that
age was associated with higher prevalence (5% in those under 50
years of age, versus 35% in those aged over 80) (Ryan 2013). The
reported incidence of delirium during an admission to hospital
spans from 3% to 29% in the published literature (Siddiqi 2006).
This ranges from 11% to 14% in general medicine, 20% to 29%
in geriatric medicine, 10% to 27% in stroke units, 47% in pallia-
tive care settings and 12% to 51% in orthopaedic units (Inouye
2014).
Delirium is associated with a range of serious adverse health out-
comes. Factors associated with poorer outcomes after an episode of
delirium include: longer duration and severity; hypoactive delir-
ium subtype; and the presence of comorbid dementia and depres-
sion (Jackson 2016a). A meta-analysis of observational study data
from older adults found those with delirium were at an increased
risk of death (hazard ratio (HR) 1.95, 95% confidence interval
(CI) 1.51 to 2.52), after adjusting for age, sex, comorbidity illness
or illness severity and baseline dementia (Witlox 2010). Evidence
indicates increased hospital length of stay is both a risk factor for
developing delirium and an outcome associated with experiencing
delirium (Ahmed 2014; Aitken 2017; Pendlebury 2015).
Delirium can have irreversible effects on an individual’s function.
A UK cohort of hospital admissions with mental health problems
found only 25% of those experiencing delirium had a clinically
important recovery in their activities of daily living six months
after the episode (Whittamore 2013). Delirium is also associated
with an increased risk in overall dependency (odds ratio (OR)
2.56, 95% CI 1.37 to 4.76) (Pendlebury 2015). This can lead
to an increased risk of requiring formal institutional care (Witlox
2010), particularly for those with delirium superimposed on an
existing dementia (Burton 2018).
Undiagnosed cognitive impairment and dementia are common in
older adults presenting with delirium (Jackson 2016b). In adults
with Alzheimer’s disease, an episode of delirium was found to ac-
celerate cognitive decline, compared to those who did not experi-
ence delirium (Fong 2009). Combined neuropathlogical and clin-
ical cohort study data have confirmed that delirium both acceler-
ates existing cognitive decline and is a risk factor for developing
dementia (Davis 2012). Delirium symptoms experienced in early
older age (60 to 69 years) are associated with poorer cognitive
function after adjustment for other dementia risk factors (Tsui
2018).
An important consideration in evaluating the impact of an episode
of delirium is both the duration of the episode and the sever-
ity, and validated measures are available to quantitatively assess
both parameters (Vasunilashorn 2016). Persistent delirium (last-
ing beyond hospital discharge) is common, estimated to affect
26% (95% CI 7.9 to 43.3%) of older hospitalised patients at
threemonths follow-up (Cole 2009).Dementia,malignancy,mul-
timorbidity, increased delirium severity, hypoactive subtype and
hypoxic illness have been independently associated with persistent
delirium (Cole 2015; Dasgupta 2010).
Significantly, delirium is distressing, particularly to family mem-
bers who witness episodes (Finucane 2017), and also may have
lasting effects on the individual patient if they recall their in-hos-
pital experiences (Grover 2015; Partridge 2013). It can also cause
distress to staff caring for these patients (Agar 2012; Partridge
2013; Waterfield 2018).
Delirium has considerable economic impact on healthcare sys-
tems and society (Leslie 2011). Estimates suggest the costs for
those with delirium are two and a half times greater per day than
for those without delirium (Leslie 2008). The cost effectiveness
of multicomponent delirium-prevention interventions has been
demonstrated using data from a non-randomised study (Akunne
2012), however there is a lack of data on cost effectiveness from
randomised trials (Siddiqi 2016).
Description of the intervention
This review will assess the effectiveness of non-pharmacological
interventions for preventing delirium in hospitalised patients out-
side the intensive care unit (ICU) setting. Non-pharmacological
interventions can be broadly divided into those with a single inter-
vention, which often target a specific risk factor, and those provid-
ing amulticomponent intervention, which targetmultiple risk fac-
tors for delirium. Multicomponent interventions are often based
around care delivered according to specific protocols, and target
risk factors such as sleep deprivation, immobility, dehydration and
sensory impairment (Inouye 1999a). The National Institute for
Health and Care Excellence (NICE) recommend assessing for the
presence of delirium risk factors in adults aged 65 years and older;
those with cognitive impairment; those with a hip fracture; and
those with severe illness at the time of hospital presentation (NICE
2010). Thereafter, it recommends a multicomponent intervention
tailored to needs and care setting, delivered by a multidisciplinary
team (NICE 2010).
How the intervention might work
A number of risk factors for delirium have been identified (Ahmed
2014; Pendlebury 2015). While some of these are non-modifi-
able factors such as age and comorbidities, there are others which
are potentially modifiable, including dehydration, sensory impair-
ment and urinary catheterisation (Ahmed 2014). Predictors of in-
cident delirium during a hospital admission include dementia, de-
pendence in activities of daily living, and increased illness severity
(O’Regan 2018). Delirium has been described as the interaction
between an individual’s baseline vulnerability (based on predis-
posing factors such as age and cognitive function) and precipi-
tating factors or insults occurring during the hospital admission
(Inouye 1996). Furthermore, it has been suggested that a combi-
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nation of risk factors for deliriummay interact to increase vulnera-
bility and that susceptibility can be scored at the time of admission
(Pendlebury 2017).
Why it is important to do this review
Delirium is common across all inpatient settings and, in view of
the serious complications, costs and consequences arising, it is a
priority for healthcare practitioners and providers. Establishing the
degree to which delirium can be prevented, and identifying evi-
dence-based strategies for prevention, will help inform evidence-
based care pathways.
The previous Cochrane Review of interventions to prevent
delirium (Siddiqi 2016) found heterogeneity among the multi-
component interventions studied; the number of “components”
tested ranged from two (Jeffs 2013; Marcantonio 2001) to 13
(Hempenius 2013). Developing an understanding around which
components are necessary and most effective would be helpful so
that robust recommendations for practice can be made.
Multicomponent interventions have been shown in randomised
trials to reduce the incidence of delirium by one-third (Martinez
2015; Siddiqi 2016). However, the reductions seen in delirium in-
cidence have not demonstrated statistically significant reductions
in length of stay or in longer-term sequelae, including mortal-
ity or the need for admission to long-term care (Hshieh 2015;
Martinez 2015). There is uncertainty about the precision and cer-
tainty of these findings and the extent to which frailty influences
outcomes (Teale 2015). Delirium and frailty (defined as ’“a di-
minished ability to compensate for stressors”) are conditions as-
sociated with poor outcomes in older people and they have been
postulated to be different manifestations of “shared vulnerability
to stress” (Quinlan 2011). This relationship is complex and poorly
understood; recent evidence suggests that mortality risk in delir-
ium is greatest in those with lower levels of frailty (Dani 2018),
although the role of illness severity in mediating this association is
not known. It would however, be helpful to identify if those with
frailty are differentially affected by delirium-prevention interven-
tions.
Some of the risk factors for delirium - including nutrition, hydra-
tion, restraint use, and iatrogenic events - can be seen as measures
of the quality of hospital care. The occurrence of delirium has
been linked to the quality of care delivered to inpatients, which
can highlight areas for improvement (Inouye 1999b). The associ-
ations between delirium and dementia mean that interventions to
prevent delirium are of interest to the wider public health agenda
of dementia prevention (Fong 2015).
Over the past decade there has been a rapid increase in the num-
ber of randomised trials of delirium-prevention interventions. In
2007, the original version of this Cochrane Review identified six
trials evaluating six interventions, only one of which was a non-
pharmacological intervention (Siddiqi 2007). The 2016 update
identified 39 trials of 22 interventions, which included seven trials
of multicomponent interventions and two other non-pharmaco-
logical interventions (Siddiqi 2016). Focusing on non-pharmaco-
logical interventions will allow a synthesis of the most contempo-
raneous specific evidence to inform and improve clinical practice.
O B J E C T I V E S
To assess the effectiveness of non-pharmacological interventions
designed to prevent delirium in hospitalised non-intensive care
unit (ICU) patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), including
cluster-RCTs.
Types of participants
We will include studies of adult participants (aged 18 years and
over) who are admitted to general-hospital settings. This will in-
clude acute and rehabilitation hospitals and sub-acute care pro-
vided in hospital. We will exclude studies conducted in commu-
nity settings, such as long-term care or nursing homes, as these
are considered in a separate Cochrane Review (Clegg 2014). If
settings are mixed, we will only include the study if data can be
extracted specifically for the hospitalised patients.
We will exclude studies of delirium associated with psychoactive
substance misuse or withdrawal, as these presentations are clini-
cally distinct. We will exclude studies conducted in intensive care
unit (ICU) and high dependency unit (HDU) settings, due to
the different populations and interventions likely to be found in
such environments. ICU settings, also known as Level 3 settings,
are those where patients require either respiratory support alone,
or support of a minimum of two organs (Intensive Care Society
2009). HDU settings, also known as Level 2 settings, are those
where patients either receive single-organ support or are stepping
down from Level 3 care; need pre-operative optimisation using in-
vasive monitoring; or need extended postoperative care (Intensive
Care Society 2009).
We will consider studies of delirium prevention in patients receiv-
ing only in-hospital specialist palliative care, and include them as a
separate subgroup analysis within this review. Delirium prevalence
in specialist palliative care settings can be very high (approximately
3Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
42% of admissions to specialist palliative care units) and the goals
of care may be different in this context (Bush 2017).
Types of interventions
We will only include non-pharmacological interventions which
have been designed and implemented to prevent delirium. Stud-
ies targeting those with “geriatric syndromes”, rather than delir-
ium specifically, will not be eligible for inclusion. We will exclude
studies administering pharmacological interventions as a means of
delirium prevention. Specifically, this includes tablets, infusions,
injectable medications, inhaled medications, or anaesthetic gases,
given to all participants in active treatment arms with the inten-
tion of preventing delirium. Studies that include correction of ab-
normal physiology using a pharmacological intervention as part of
a multicomponent intervention, e.g. administration of oxygen in
presence of low oxygen saturations, will be eligible for inclusion.
Eligible trials include those of multicomponent interventions or
single-component interventions targeting a specific risk factor (e.g.
sleep, hydration, re-orientation). These may include trials of an
intervention compared to the usual care available or to an active
control intervention. Interventions may be implemented at the
level of the ward or department providing care, or at the individual
level.
Types of outcome measures
We will include all studies which report any of the primary or
secondary outcomes. We have prespecified clinically important
secondary outcomes and adverse outcomes which are relevant to
patients, families and healthcare providers.
Primary outcomes
1. Incidence of delirium, using a validated diagnostic method
(studies using only a positive screening test in the absence of a
formal diagnosis will be excluded).
2. Mortality as an inpatient, between one and three months,
six and 12 months, and beyond 12 months from randomisation.
3. New diagnosis of dementia, made between one and three
months, six and 12 months, and beyond 12 months from
randomisation.
Secondary outcomes
1. Duration of delirium episode, measured in days.
2. Peak severity of delirium, measured using validated
instruments including the Memorial Delirium Assessment Scale
(MDAS) (Breitbart 1997), Delirium Rating Scale (DRS)
(Trzepacz 1988), and Delirium Rating Scale Revised 1998
(DRS-R-98) (Trzepacz 2001).
3. Length of hospital admission, measured in days.
4. Use of new psychotropic medication during hospital
admission.
5. Activities of daily living, measured using a validated
instrument including the Barthel Index (Mahoney 1965) and
Katz Index (Katz 1963), between one and three months, six and
12 months, and beyond 12 months from randomisation.
6. Quality of life, measured using a validated patient reported
measure, between one and three months, six and 12 months, and
beyond 12 months from randomisation.
7. Carer’s quality of life, using a validated carer-reported
measure, between one and three months, six and 12 months, and
beyond 12 months from randomisation.
8. Withdrawal from protocol by participants.
Adverse outcomes
1. Readmission to hospital within 30 days of discharge.
2. Progression of existing dementia, measured using a
validated instrument, between one and three months, six and 12
months, and beyond 12 months from randomisation.
3. New care-home admission at discharge and between one
and three months, six and 12 months, and beyond 12 months
from randomisation.
4. Falls.
5. Pressure ulcers.
We will use GRADEpro Guideline Development Tool software
(GRADEpro 2014) to determine the overall quality of the evi-
dence and to generate a ’Summary of findings’ table for the out-
comes: incidence of delirium, inpatient mortality, new diagnosis
of dementia, duration of delirium, peak delirium severity, length
of hospital admission, and discharge to new long-term care place-
ment.
Search methods for identification of studies
Electronic searches
We will search the specialised register of the Cochrane
Dementia and Cognitive Impairment Group (ALOIS) (
www.medicine.ox.ac.uk/alois).Wewill search for all RCTs of non-
pharmacological interventions for preventing delirium. The Infor-
mation Specialists of the Cochrane Dementia and Cognitive Im-
pairment Group maintain ALOIS, which contains studies about
dementia and cognitive impairment identified from the following.
1. Monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO and
LILACs.
2. Monthly searches of a number of trials registers: the
metaRegister of Controlled Trials, the Umin Japan Trial Register,
the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) portal (which covers
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ClinicalTrials.gov, ISRCTN Registry, the Chinese Clinical Trials
Register, the German Clinical Trials Register, the Iranian
Registry of Clinical Trials and The Netherlands Clinical Trials
Register, plus others).
3. Quarterly searches of the Cochrane Library’s Central
Register of Controlled Trials (CENTRAL).
4. Monthly searches of the grey literature sources: ISI Web of
Science Core Collection.
To view a list of all sources searched for ALOIS, please visit the
ALOIS website ( www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed
on the Cochrane Dementia and Cognitive Improvement Group’s
website: https://dementia.cochrane.org/searches.
We will run additional searches in MEDLINE, Embase,
PsycINFO, CINAHL, ClinicalTrials.gov and the WHO ICTRP
portal to ensure that the searches are as comprehensive and as up-
to-date as possible. We have presented the search strategy that will
be used for the retrieval of reports of trials from MEDLINE (via
the Ovid SP platform) in Appendix 1. There will be no time or
language restrictions on literature searches.
Searching other resources
Wewill examine reference lists from identified articles and relevant
systematic reviews to identify any additional potential trials to re-
view for eligibility. We will search the ClinicalTrials.gov database,
to identify any relevant ongoing trials. We will compare the trials
that meet our review inclusion criteria with the trials register to
identify any trials where results have been unpublished. We will
contact the lead author of any unpublished trials, to ask if they are
prepared to share their results (we will examine these against the
published protocols to ensure they have been consistently anal-
ysed).
Data collection and analysis
Selection of studies
We will directly import the results of the literature searches into
Covidence software (Covidence 2017). This will automatically re-
move direct duplicate records. Thereafter, two review authors, with
experience in conducting systematic reviews, will independently
screen the titles and abstracts of all identified articles and remove
irrelevant results. We will resolve any disagreements by discussion,
involving a third review author if necessary. Two review authors
will then independently examine the full-text articles of poten-
tially relevant articles against the review eligibility criteria. We will
resolve any disagreements by consensus with a third review author.
If we are unable to determine eligibility based on the available
information, for example if only an abstract is identified, we will
contact the study authors for clarification and additional data as
necessary.We will list all articles excluded after full-text assessment
in the ’Characteristics of excluded studies’ table, with reasons for
exclusion. We will present a PRISMA diagram to summarise the
study selection process.
Data extraction and management
We will create a data extraction tool, adapted from the version
used in the previous update of this review. Two authors will extract
data using this tool. Two authors will discuss any disagreements
regarding data extraction, involving a third author if necessary.
For our component-based analysis we will extract the informa-
tion provided on the description of the components of the inter-
ventions in as much detail as possible. In the previous version of
the review, these were tabulated into 20 categories, providing an
overview of included components (Siddiqi 2016). Ideally, compo-
nents should be defined at a level that clinical recommendations
could be based on, for example, they should include a measure
of duration and intensity as well as the nature of the intervention
delivered to participants. However, we appreciate that this may
not be possible given the descriptions available. In the event that
such detail is lacking, we will correspond with study authors to try
to obtain the required information.
If it is not possible to define components at such a level, we will
define components at broader levels, possibly based on the type of
intervention or intensity or risk factor it is targeting, or a combi-
nation of these. Such grouping will only occur following consul-
tation of clinical expertise from two review authors who agree the
classification has clinical validity.
We will conduct sensitivity analyses where there is uncertainty
over the optimal way to define components by defining alternative
component definitions, repeating the analysis and assessing the ro-
bustness of results to such changes. Similarly, where a component
is only given to a fraction of a trial arm, we will explore changes
in classification definitions via sensitivity analysis.
We will use Review Manager 5 to produce tables which docu-
ment the characteristics of included, excluded and ongoing trials
(Review Manager 2014). We will create ’Summary of findings’
tables using GRADEPro GDT (GRADEpro 2014) software. If
there are multiple publications reporting the findings of a single
study, we will extract these onto a single data extraction form.
Assessment of risk of bias in included studies
Two review authors will independently perform a ’Risk of bias’
assessment at the time of data extraction. We will evaluate each
study using the criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2018). We will assess
trials for the domains of: bias arising from the randomisation pro-
cess; bias due to deviations from intended interventions; bias due
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to missing outcome data; bias in measurement of the outcome;
and bias in selection of the reported result.
Cluster-RCTs are subject to additional biases: recruitment bias
(recruitment of individual study participants after randomisation
of clusters), chance between-cluster baseline imbalances due to a
small number of clusters, loss of clusters (e.g. withdrawal of a study
site), not accounting for clustering during the analysis (incorrect
unit of analysis issues), or bias introduced through combining
data from cluster-randomised and individually-randomised trials
in meta analyses (risk of underestimation of treatment effects).
We will judge each of these domains as being at either high, low or
unclear risk of bias in each study.Wewill resolve any disagreements
by discussion between the two review authors, involving a third
author if necessary.We will produce summary tables and figures of
the ’Risk of bias’ assessment, with justification, in ReviewManager
5 (Review Manager 2014).
Measures of treatment effect
We anticipate the outcome data to include continuous and di-
chotomous measures. For continuous outcomes we will calcu-
late between-group (intervention versus control) mean differences
with 95% confidence intervals (CIs). If an identified study does
not report data to calculate the primary outcome, we will contact
the authors directly to ask them to share these data.
Unit of analysis issues
We expect some included studies to use a cluster-randomised de-
sign.Where these studies have analysed data using statistical meth-
ods that account for clustering, we will extract the adjusted ef-
fect measures (risk ratio or hazard ratio) and their 95% CIs. If
an included study has performed unadjusted analyses we will ap-
proximate corrected analyses by extracting data on the number
of clusters, mean size of each cluster, primary outcome data and
estimates of intra-cluster correlation coefficient (ICC). If approxi-
mately corrected analyses are not possible, then we will extract the
primary data and calculate risk ratios with 95% CIs.
Dealing with missing data
We will report missing data for each included study, including
reporting the number of participants included in the final analysis
as a proportion of all participants in the study. We will perform
available case analysis, including data on those whose outcomes
are known. We will contact study authors to try to obtain data not
reported in the publication. We will report incomplete outcome
assessment in the ’Risk of bias’ table for each study, including an
assessment of the potential impact of missing data on the results.
Assessment of heterogeneity
It is anticipated that the identified trials will be both clinically and
methodologically heterogeneous. We will describe clinical hetero-
geneity. If the data are considered appropriate for quantitative syn-
thesis, we will calculate statistical heterogeneity and describe it us-
ing the I2 statistic (Higgins 2002). Interpretation of the I2 statistic
will be in accordance with guidance in the Cochrane Handbook
(Deeks 2019).
Assessment of reporting biases
We will compare the studies included in our review with clinical
trial registries, to identify trials with unpublished results. We will
compare the protocols of published studies included in the review
against their protocols to check adherence.
Data synthesis
Where it is appropriate, we will undertake meta-analysis of ex-
tracted data using Review Manager 5 (Review Manager 2014).
We will performmeta-analyses using a random-effects model. We
will calculate pooled risk ratios with 95% CIs for dichotomous
outcomes (intervention versus control), and pooled mean differ-
ences with 95% CIs for continuous outcomes. If studies use dif-
ferent instruments to measure the same continuous outcome, we
will calculate the standardised mean difference.We will synthesise
outcomes from appropriately adjusted cluster-RCTs.Wewill mea-
sure statistical heterogeneity using the I2 statistic (Higgins 2002).
We will perform data synthesis only where it is considered that
the identified studies are clinically homogenous, such that pool-
ing of data is appropriate and valid comparisons can be made. If
the clinical heterogeneity is significant, we will report a narrative
evidence synthesis.
In addition to the standard meta-analysis, if the available data per-
mit it, we will fit a component level network meta-analysis model
to the data to explore and estimate the effectiveness of individual
components of the interventions (Welton 2009). The National
Institute for Health Research Complex Review Support Unit will
perform this analysis. Such an analysis attempts to decompose the
estimates of effect in multicomponent interventions so that the
effectiveness of individual components can be estimated. As well
as providing clinical insight, the optimum combination of com-
ponents can also be considered.With modest numbers of trials, an
additive model often has to be used, which assumes the effects of
components add together directly when combined, and no inter-
actions between components affect their effectiveness. With more
data, the additive assumption can be relaxed and interaction terms
included in the model. When fitting different models is possible,
clinical plausibility and statistical goodness-of-fit of the models
will dictate which model is used in the final analysis. Irrespective
of whethermultiplemodels are fit, howwell themodel fits the data
will be examined and reported via goodness-of-fit statistics. The
WinBUGS software will be used for this analysis (WinBUGS).
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Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses for participants in trials con-
ducted inmedical versus surgical inpatient settings; those receiving
palliative care only versus those receiving other medical or surgical
treatment; those with and without a diagnosis of dementia (mea-
sured using a validated diagnostic instrument); and those who are
considered to have frailty versus those who are not (measured us-
ing a validated instrument).
Sensitivity analysis
We will perform a sensitivity analysis where appropriate follow-
ing assessment of the risk of methodological bias in the included
studies.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. Delirium/
2. deliri*.mp.
3. “acute confusion*”.ti,ab.
4. “acute organic psychosyndrome”.ti,ab.
5. “acute brain syndrome”.ti,ab.
6. “metabolic encephalopathy”.ti,ab.
7. “acute psycho-organic syndrome”.ti,ab.
8. “clouded state”.ti,ab.
9. “clouding of consciousness”.ti,ab.
10. “exogenous psychosis”.ti,ab.
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11. “toxic psychosis”.ti,ab.
12. “toxic confusion”.ti,ab.
13. Delirium, Dementia, Amnestic, Cognitive Disorders/su [Surgery]
14. obnubilat*.ti,ab.
15. or/1-14
16. Primary Prevention/
17. prevent*.mp.
18. reduc*.ti,ab.
19. stop*.ti,ab.
20. taper*.ti,ab.
21. avoid*.ti,ab.
22. “cut* down”.ti,ab.
23. or/16-22
24. 15 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomi?ed.ab.
28. placebo.ab.
29. drug therapy.fs.
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. or/25-32
34. (animals not (humans and animals)).sh.
35. 33 not 34
36. 35 and 24
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